SUITE 310, 815 W. HASTINGS STREET, VANCOUVER, A1
Announces $200 Million Private Placement for Migraine Prevention Pipeline
Pharmaceuticals and Mentari Therapeutics Announce Amendment to Merger Agreement and Filing of Registration Statement on Form S-4
Other Events
Investor Webcast Script: Scheduled for 5.19.26, 8:30AM ET
Amends Preferred Investment Options
Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update
InMed Pharmaceuticals Files Prospectus Supplement for Common Shares
Q3
Q2
Q1
Amended Annual Report
FY 2025
Prospectus Filed Pursuant to Rule 425
S-4
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Schedule 13D - Ownership Report
Initial Statement of Beneficial Ownership
Correspondence
Submission Upload